Given the pivotal role of the B-cell receptor (BCR) in sustaining the survival and the proliferation of CLL cells, most targeted agents have been developed against Bruton tyrosine kinase (BTK) and BCL2 (B-cell lymphoma 2) (Figure 1). Here, BTK is linked to B-cell chronic lymphocytic leukemia.